How Japan's NHI Drug Price Revision Works: A Guide for Global Pharma Teams

Japan's National Health Insurance (NHI) drug pricing system is one of the most rigorous in the world. For global market access teams, understanding how prices are set — and revised — is essential for launch sequencing, international reference pricing (IRP) management, and competitive intelligence. This guide covers the full cycle from first listing to revision.

How NHI Drug Prices Are Initially Set

When a new drug receives manufacturing approval in Japan, the Central Social Insurance Medical Council (Chuikyo) sets its NHI price before it can be reimbursed. The listing price is calculated using one of two methods:

• Similar efficacy comparison (類似薬効比較方式): The most common method. The new drug is benchmarked against an existing NHI-listed comparator. Premiums of 5–120% can be added for innovation, orphan designation, pediatric use, or market expansion.
• Cost calculation method (原価計算方式): Used when no appropriate comparator exists. MHLW derives a price from manufacturing costs, R&D investment, and a profit margin. This method is less predictable and more negotiated.

Once listed, the drug's price appears in the MHLW official drug price standard (薬価基準), published as Excel files and updated with every revision.

The Revision Cycle

Japan has historically revised NHI prices every two years. Since 2021, the government has moved to annual revisions, though the scope differs:

Year	Type	Scope
April (even years)	Full revision	All listed drugs repriced
April (odd years)	Interim revision	Drugs with market price deviation above threshold
October	Special revision	New listings and specific policy adjustments

The April 2026 revision was a full revision affecting all 17,000+ listed products. The April 2025 interim revision targeted drugs where the market transaction price had fallen more than 5% below the NHI listed price — a common outcome as hospitals negotiate volume discounts with wholesalers.

What Drives Price Cuts

The single largest driver of NHI price reductions is the drug price survey (薬価調査). MHLW conducts this survey every other year, collecting actual transaction prices between wholesalers and medical institutions for every listed drug. The gap between the NHI listed price and the actual market price — called the R-zone (乖離率) — determines how much each drug's price is cut.

The standard adjustment formula:

New NHI Price = Market Price × (1 + adjustment rate)

The adjustment rate is typically set at 2%, giving manufacturers a small cushion above market prices. Drugs with very large R-zones face steeper cuts. In the 2024 full revision, the average price reduction across all drugs was approximately 5.1%, with generics seeing larger cuts than innovator products on average.

Additional mechanisms that trigger price reductions:

• Market expansion repricing (市場拡大再算定): If a drug's sales significantly exceed the forecast at time of listing (typically 1.5× the projected peak sales), its price is reduced mid-cycle. Blockbusters like anti-PD-1 agents have been subject to multiple rounds of market expansion repricing.
• Re-examination repricing: Following post-marketing re-examination data submission, MHLW may adjust the price.
• Long-listed drug policy: Drugs that have been on the NHI list for many years face additional annual price pressure separate from the main revision cycle.

How Generics Are Priced

Generic drugs in Japan are listed at a fixed percentage of the originator's NHI price at the time of generic entry:

• First generic entrants: 50% of the originator price (reduced from 60% in 2018)
• Subsequent generics (if 10 or more products): 40% of the originator price

The originator's price is simultaneously reduced when generics enter: typically to 70% of its pre-generic price, and further to 50% once generic penetration reaches a government target level.

Japan has a stated policy goal of increasing generic dispensing to 80%+ of prescriptions. Financial incentives for pharmacies and hospitals are built into the reimbursement system, and branded products in high-generic-penetration categories face accelerating price pressure.

What Global Teams Need to Monitor

For market access professionals outside Japan, three things are most important to track:

1. IRP exposure on new listings. Several markets — including Italy, Spain, and some Middle Eastern countries — reference Japanese NHI prices directly or indirectly. A Japan listing at a low price creates immediate downstream IRP pressure. The timing and price level of Japan listing relative to other markets matters.

2. Market expansion repricing triggers. If your product is growing faster than the MHLW forecast in Japan, a mid-cycle price cut may be incoming. The repricing can be steep — 25–50% in cases of very large sales overruns. This is increasingly relevant for oncology and rare disease products that receive broad label expansions post-launch.

3. Revision cycle timing. The next full revision is April 2028. The interim revision in April 2027 will affect drugs whose market transaction price has drifted. If your product's hospital contract prices are significantly below NHI, expect a proportional cut in 2027. Monitoring the gap continuously — not just at revision time — gives you time to adjust contracting strategy.

Reading the Official Data

MHLW publishes the complete NHI drug price list as Excel files after each revision. The files are organized by drug category: oral drugs (), injectable drugs (), and external-use drugs (). Column headers are in Japanese, and the files do not include English ingredient names or WHO INN terms, which makes systematic analysis difficult for non-Japanese teams.

The revision history files follow a consistent naming convention based on effective date, making it possible to reconstruct price trajectories for any listed drug across multiple revisions — useful for benchmarking, due diligence, and IRP scenario modeling.